Effect of Oral Zinc Sulfate Supplementation on Enzymes of Urate Pathway
Overview
Although many reports have investigated the relationship between subfertility and uric acid levels in semen, to the best of author knowledge, there is no study have been published to yet focus on the effects of asthenospermia treatments, such as given an oral zinc supplementation, on the activity of urate-related enzymes, which are important in fertility of human.
Full Title of Study: “Effect of Oral Zinc Sulfate Supplementation on Enzymes of Urate Pathway in Spermatozoa and Seminal Plasma of Iraqi Asthenospermic Patients”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: June 1, 2012
Detailed Description
The present study was designed to investigate the effect of zinc supplementation on the qualitative and quantitative characteristics of semen, along with uric acid levels and urate-related enzymes in the seminal plasma and spermatozoa of asthenospermic males.
Interventions
- Dietary Supplement: Zinc Sulfate
- The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
Arms, Groups and Cohorts
- Experimental: Zinc sulfate
- 60 subfertile (age 32.5±3.23 year) men with asthenozoospermia was treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
- No Intervention: Healthy control
- 60 fertile (age 31.6±3.3 year) men, no treatment.
Clinical Trial Outcome Measures
Primary Measures
- Measurement the uric acid level in spermatozoa and seminal plasma by using spectrophotometer.
- Time Frame: up to three months.
- Clinical parameter
Secondary Measures
- Measurement the adenosine deaminase activity in spermatozoa and seminal plasma by using spectrophotometer.
- Time Frame: up to three months.
- Enzyme
- Measurement the xanthine oxidase activity in spermatozoa and seminal plasma by using spectrophotometer.
- Time Frame: up to three months.
- Enzyme
- Measurement the 5′-nucleotidase activity in spermatozoa and seminal plasmaby using the spectrophotometer.
- Time Frame: up to three months.
- Enzyme
Participating in This Clinical Trial
Inclusion Criteria
- The presence of asthenozoospermia in the semen sample. – Must be unable to reproduce. Exclusion Criteria:
- the absence of endocrinopathy, varicocele, and female factor infertility. Smokers and alcoholic men were excluded from the study because of their recognized high seminal ROS levels and decreased antioxidant levels.
Gender Eligibility: Male
Male that undergo the presence of asthenozoospermia in the semen sample.
Minimum Age: 26 Years
Maximum Age: 36 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- Babylon University
- Collaborator
- Ministry of Health, Iraq
- Provider of Information About this Clinical Study
- Principal Investigator: mahmoud hussein hadwan, Principal Investigator Dr. Mahmoud Hussein Hadwan – Babylon University
- Overall Official(s)
- Abdul Razzaq A. Alsalman, PhD, Study Chair, University of Babyblon
- Lamia A. Almashhedy, PhD, Study Director, University of Babyblon
- Mahmoud Hussein Hadwan, PhD, Principal Investigator, University of Babyblon
- Abdulsamie H Alta’ee, PhD, Study Director, University of Babyblon
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.